Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Expands By 94.5%

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 115,900 shares, a growth of 94.5% from the February 28th total of 59,600 shares. Based on an average daily trading volume, of 1,850,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.3% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Maxim Group started coverage on Kazia Therapeutics in a research note on Thursday, February 6th. They issued a “buy” rating and a $3.00 target price on the stock.

Kazia Therapeutics Trading Down 7.4 %

Kazia Therapeutics stock traded down $0.07 during mid-day trading on Friday, hitting $0.88. 69,902 shares of the company traded hands, compared to its average volume of 852,788. The stock has a fifty day moving average price of $1.09 and a 200-day moving average price of $3.00. Kazia Therapeutics has a one year low of $0.76 and a one year high of $15.80.

Institutional Trading of Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. Barclays PLC purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned about 2.38% of Kazia Therapeutics as of its most recent SEC filing. 30.89% of the stock is currently owned by institutional investors and hedge funds.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.